Association between the triglyceride glucose index and coronary collateralization in coronary artery disease patients with chronic total occlusion lesions.
Chronic total occlusion
Coronary collateralization
Insulin resistance
Triglyceride glucose index
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
27
08
2021
accepted:
05
10
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
19
2
2022
Statut:
epublish
Résumé
Recent studies have substantiated the role of the triglyceride glucose (TyG) index in predicting the prognosis of coronary artery disease (CAD) patients, while no relevant studies have revealed the association between the TyG index and coronary collateralization in the event of coronary chronic total occlusion (CTO). The current study intends to explore whether, or to what extent, the TyG index is associated with impaired collateralization in CAD patients with CTO lesions. The study enrolled 1093 CAD patients undergoing cardiac catheterization for at least one CTO lesion. Data were collected from the Beijing Anzhen Hospital record system. The degree of collaterals was determined according to the Rentrop classification system. The correlation between the TyG index and coronary collateralization was assessed. Overall, 318 patients were included in a less developed collateralization (Rentrop classification 0-1) group. The TyG index was significantly higher in patients with impaired collateralization (9.3±0.65 vs. 8.8±0.53, P<0.001). After adjusting for various confounding factors, the TyG index remained correlated with the occurrence of impaired collateralization, with odds ratios (ORs) of 1.59 and 5.72 in the T2 and T3 group compared with the first tertile group (P<0.001). In addition, subgroup analysis showed that higher TyG index values remained strongly associated with increased risk of less developed collateralization. To compare the risk assessment efficacy for the formation of collateralization between the TyG index and other metabolic abnormality indicators, an area under the receiver-operating characteristic (ROC) curve (AUC) was obtained. A significant improvement in the risk assessment performance for impaired collateralization emerged when adding the TyG index into a baseline model. The increased TyG index is strongly associated with less developed collateralization in CAD patients with CTO lesions and its risk assessment performance is better than single metabolic abnormality indicators.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have substantiated the role of the triglyceride glucose (TyG) index in predicting the prognosis of coronary artery disease (CAD) patients, while no relevant studies have revealed the association between the TyG index and coronary collateralization in the event of coronary chronic total occlusion (CTO). The current study intends to explore whether, or to what extent, the TyG index is associated with impaired collateralization in CAD patients with CTO lesions.
METHODS
METHODS
The study enrolled 1093 CAD patients undergoing cardiac catheterization for at least one CTO lesion. Data were collected from the Beijing Anzhen Hospital record system. The degree of collaterals was determined according to the Rentrop classification system. The correlation between the TyG index and coronary collateralization was assessed.
RESULTS
RESULTS
Overall, 318 patients were included in a less developed collateralization (Rentrop classification 0-1) group. The TyG index was significantly higher in patients with impaired collateralization (9.3±0.65 vs. 8.8±0.53, P<0.001). After adjusting for various confounding factors, the TyG index remained correlated with the occurrence of impaired collateralization, with odds ratios (ORs) of 1.59 and 5.72 in the T2 and T3 group compared with the first tertile group (P<0.001). In addition, subgroup analysis showed that higher TyG index values remained strongly associated with increased risk of less developed collateralization. To compare the risk assessment efficacy for the formation of collateralization between the TyG index and other metabolic abnormality indicators, an area under the receiver-operating characteristic (ROC) curve (AUC) was obtained. A significant improvement in the risk assessment performance for impaired collateralization emerged when adding the TyG index into a baseline model.
CONCLUSIONS
CONCLUSIONS
The increased TyG index is strongly associated with less developed collateralization in CAD patients with CTO lesions and its risk assessment performance is better than single metabolic abnormality indicators.
Identifiants
pubmed: 34689767
doi: 10.1186/s12944-021-01574-x
pii: 10.1186/s12944-021-01574-x
pmc: PMC8543811
doi:
Substances chimiques
Blood Glucose
0
Triglycerides
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
© 2021. The Author(s).
Références
BMJ. 2021 Jun 16;373:n1332
pubmed: 34135011
Circulation. 1974 Oct;50(4):831-7
pubmed: 4425386
Medicine (Baltimore). 2018 Sep;97(39):e12587
pubmed: 30278570
Cardiovasc Diabetol. 2018 Mar 21;17(1):41
pubmed: 29562908
Eur Heart J. 2013 Sep;34(34):2674-82
pubmed: 23739241
Circ Cardiovasc Interv. 2017 Jun;10(6):
pubmed: 28606999
Circulation. 2001 Dec 4;104(23):2784-90
pubmed: 11733395
Circulation. 2012 Jun 26;125(25):3211-9
pubmed: 22733335
Diabetes Care. 2019 Aug;42(8):1569-1573
pubmed: 31182490
Scott Med J. 1963 Dec;8:466-74
pubmed: 14089222
Cardiovasc Diabetol. 2013 Nov 08;12:165
pubmed: 24209601
Diabetes Metab Syndr Obes. 2019 Nov 01;12:2251-2259
pubmed: 31807040
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2351-2362
pubmed: 32917496
Cardiovasc Diabetol. 2020 Jun 13;19(1):80
pubmed: 32534586
Nutrients. 2019 Nov 19;11(11):
pubmed: 31752391
J Investig Med. 2012 Jun;60(5):808-12
pubmed: 22460232
Medicine (Baltimore). 2020 Jan;99(2):e18753
pubmed: 31914097
Front Endocrinol (Lausanne). 2021 Apr 23;12:644159
pubmed: 33967958
Diagnostics (Basel). 2020 Dec 12;10(12):
pubmed: 33322810
Dis Markers. 2019 Jun 11;2019:6891537
pubmed: 31281548
PLoS One. 2019 Mar 7;14(3):e0212963
pubmed: 30845237
J Diabetes Res. 2020 Oct 12;2020:7489795
pubmed: 33123598
JACC Cardiovasc Interv. 2017 May 8;10(9):906-914
pubmed: 28473112
J Cardiovasc Pharmacol. 2020 Aug;76(2):173-180
pubmed: 32569017
J Atheroscler Thromb. 2021 Feb 03;:
pubmed: 33536384
JACC Cardiovasc Interv. 2020 Jan 13;13(1):1-19
pubmed: 31918927
Sci Rep. 2021 May 11;11(1):10036
pubmed: 33976344
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):179-86
pubmed: 22342811
JACC Cardiovasc Interv. 2021 Feb 22;14(4):361-373
pubmed: 33602431
Circulation. 2019 Jul 30;140(5):420-433
pubmed: 31356129
Diabetes Res Clin Pract. 2020 Dec;170:108528
pubmed: 33157116
Angiology. 2018 Oct;69(9):795-802
pubmed: 29544348
Cardiovasc Diabetol. 2021 May 10;20(1):104
pubmed: 33971883
BMJ Open. 2016 Jul 13;6(7):e011105
pubmed: 27412101
Ann Med. 2016;48(1-2):83-8
pubmed: 26790524
Eur Heart J. 2009 Apr;30(7):840-9
pubmed: 19164335
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Cardiovasc Diabetol. 2020 Jul 23;19(1):116
pubmed: 32703284
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
JACC Cardiovasc Interv. 2015 Feb;8(2):245-253
pubmed: 25700746
J Atheroscler Thromb. 2020 Nov 13;:
pubmed: 33191314
Lipids Health Dis. 2020 Oct 15;19(1):226
pubmed: 33059672
Mol Ther. 2013 Apr;21(4):725-38
pubmed: 23403495
EuroIntervention. 2021 Aug 11;:
pubmed: 34374343
J Am Coll Cardiol. 1985 Mar;5(3):587-92
pubmed: 3156171